ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 18.31% | -42.03% | 86.24% | -475.71% | 53.73% |
| Total Depreciation and Amortization | -0.51% | -0.65% | -10.72% | 5.72% | 26.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.26% | -5.71% | -98.92% | 13,096.94% | -103.11% |
| Change in Net Operating Assets | -58.45% | 1,568.01% | -119.28% | 123.73% | -292.42% |
| Cash from Operations | -238.62% | 83.46% | 5.46% | 67.74% | -73.76% |
| Capital Expenditure | -- | 100.00% | 82.14% | -440.61% | -480.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 82.14% | -440.61% | -100.71% |
| Total Debt Issued | -25.00% | -- | -- | -- | -100.00% |
| Total Debt Repaid | -2,919.77% | 74.78% | -2.10% | 39.38% | 82.56% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 224.58% | 190.75% | -3.01% | 40.24% | -103.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -281.02% | 95.78% | 9.03% | 64.15% | -159.05% |
